Circle Medical founders launch Clara AI primary care with $12M
What's the deal? George Favvas, who built telehealth company Circle MedicalDealroom has a profile for this one. Try Dealroom → into a $100M-a-year business, has launched Clara AI — a primary care platform where an AI system reads patient histories, drafts prescriptions, and prepares lab orders before routing everything to a licensed physician for final approval.
The San Francisco startup raised $12M in pre-seed funding from Y Combinator, A.Capital, SV Angel, Liquid 2 Ventures, and a roster of angel investors. It's a notable sum for a company at such an early stage.
Clara offers three membership tiers — $25, $50, and $150 per month — none of which accept insurance. The basic plan covers unlimited AI chats and doctor-reviewed prescriptions. Higher tiers add video visits, wearable integration, and comprehensive biomarker testing. All plans qualify for HSA and FSA reimbursement.
The platform claims to sync medical records from a network of more than 150,000 hospitals, labs, and pharmacies, though that figure hasn't been independently verified. It treats standard primary care conditions — allergies, hypothyroidism, type 2 diabetes, UTIs, weight management — but won't prescribe controlled substances.
Why now? Favvas brought Circle Medical co-builders Caitlin Swift and Zeeshan Ahmed along for the new venture. Swift oversaw roughly a million telehealth encounters annually at Circle Medical; Ahmed led product design there after stints at Meta and Instagram.
The team also recruited Brendan Levy, founder of HeyDoctorDealroom has a profile for this one. Try Dealroom → (YC S17) and former GoodRx executive, as chief medical officer, and Claudia Tucker, previously SVP of government affairs at Teladoc, as VP of regulatory affairs. Tucker's hire signals the founders understand the compliance gauntlet ahead.
What could go wrong? The cash-pay model sidesteps insurance reimbursement headaches but limits the addressable market to patients willing to pay out of pocket. Every clinical decision still requires a human physician's sign-off — a legal necessity, but also a potential bottleneck as the platform scales.
AI-first healthcare draws intense regulatory scrutiny. Clara's careful framing — the AI "isn't a physician" — is more than legal boilerplate. It's the architecture the entire business rests on. Any misstep in that physician-oversight model could invite enforcement action or erode patient trust.
The signal: Clara sits at the intersection of two accelerating trends: the commoditisation of routine primary care and the rapid deployment of AI as a clinical co-pilot. The bet is that most primary care interactions don't require a doctor's full attention from start to finish — just their judgement at the decision point.
If Clara can prove that model works safely at scale, it could reshape how millions of people access basic healthcare. The founders' track record at Circle Medical gives them credibility few AI health startups can match. But credibility and clinical safety are different things, and regulators will be watching closely.
